Lussier Mia E, Gionfriddo Michael R, Graham Jove H, Wright Eric A
Center for Pharmacy Innovation and Outcomes, Geisinger Health System, Danville, PA, USA.
Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, Binghamton University, Johnson City, NY, USA.
J Gen Intern Med. 2024 Feb;39(2):195-200. doi: 10.1007/s11606-023-08435-6. Epub 2023 Oct 2.
Despite type 2 diabetes guidelines recommending against the use of sulfonylureas in older adults and for the use of sodium-glucose cotransporter-2 inhibitors (SGLT2) and glucagon-like peptide-1 agonists (GLP1s) in patients with atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), and heart failure (HF), real-world guideline-concordant prescribing remains low. While some factors such as cost have been suggested, an in-depth analysis of the factors associated with guideline-concordant prescribing is warranted.
To quantify the extent of guideline-concordant prescribing in an integrated health care delivery system and examine provider and patient level factors that influence guideline-concordant prescribing.
We performed a cross-sectional study.
Participants were included if they had a diagnosis of type 2 diabetes, were prescribed a second-line diabetes medication between January 1, 2018 and December 31, 2020 and were at least 65 years old at the time of this second-line prescription.
Our outcome of interest was guideline-concordant prescribing. The definition of guideline-concordant prescribing was based on American Diabetes Association and American Geriatric Society recommendations as well as expert consensus. Factors affecting guideline concordant prescribing included patient demographics and provider characteristics among others.
We included 1,693 patients of which only 50% were prescribed guideline-concordant medications. In a subgroup of 843 patients with cardiorenal conditions, only 30% of prescriptions were guideline concordant. Prescribing of guideline-concordant prescriptions was more likely among pharmacists than physicians (RR 1.34, 95% CI 1.19-1.51, p<0.001) and in endocrinology practices compared to primary care practices (RR 1.41 95% CI 1.16-1.72, p=0.007). Additionally, guideline concordant prescribing increased over time (42% in 2018 vs 53% in 2019 vs 53% in 2020, p<0.001).
Guideline-concordant prescribing remains low in older adults, especially among those with cardiorenal conditions. Future studies should examine barriers to prescribing guideline-concordant medications and interventions to improve guideline-concordant prescribing.
尽管2型糖尿病指南建议老年人不要使用磺脲类药物,并建议动脉粥样硬化性心血管疾病(ASCVD)、慢性肾脏病(CKD)和心力衰竭(HF)患者使用钠-葡萄糖协同转运蛋白2抑制剂(SGLT2)和胰高血糖素样肽1激动剂(GLP1),但在现实世界中,符合指南的处方率仍然很低。虽然有人提出了一些因素,如成本,但有必要对与符合指南的处方相关的因素进行深入分析。
量化综合医疗服务系统中符合指南的处方程度,并研究影响符合指南处方的提供者和患者层面的因素。
我们进行了一项横断面研究。
如果参与者被诊断为2型糖尿病,在2018年1月1日至2020年12月31日期间被开具二线糖尿病药物处方,且在开具该二线处方时年龄至少为65岁,则纳入研究。
我们感兴趣的结果是符合指南的处方。符合指南的处方定义基于美国糖尿病协会和美国老年医学会的建议以及专家共识。影响符合指南处方的因素包括患者人口统计学特征和提供者特征等。
我们纳入了1693名患者,其中只有50%的患者被开具了符合指南的药物。在843名患有心肾疾病的亚组患者中,只有30%的处方符合指南。药剂师开具符合指南处方的可能性高于医生(相对风险1.34,95%置信区间1.19-1.51,p<0.001),与初级保健机构相比,内分泌科开具符合指南处方的可能性更高(相对风险1.41,95%置信区间1.16-1.72,p=0.007)。此外,符合指南的处方率随时间增加(2018年为42%,2019年为53%,2020年为53%,p<0.001)。
老年人中符合指南的处方率仍然很低,尤其是在心肾疾病患者中。未来的研究应探讨开具符合指南药物的障碍以及改善符合指南处方的干预措施。